UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111).

Autor:	Tam, C.S., Wang, M., Simpson, D., Opat, S., Cull, G., Munoz, J., Phillips, T.J., Kim, W., Atwal, S., Wei, R., Huang, J., Elstrom, R., Trotman, J.
Předmět:	ANAPLASTIC lymphoma kinase MANTLE cell lymphoma PROTEIN-tyrosine kinases
Zdroj:	Hematological Oncology; Jun2019 Supplement S2, Vol. 37, p245-247, 3p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text